Skokie, Illinois
With the dedication today of its new 24,000-square-foot facility at the Illinois Science + Technology Park in Skokie, Vetter may enable life-sciences firms to streamline their early development process and cut time to market. Vetter, a contract manufacturer, produces aseptically pre-filled injection systems including syringes, vials and injection pens and is mainly engaged in the field of fill and finishing of compounds indicated for conditions such as cancer, Parkinson’s disease, and inflammatory and autoimmune disorders. Vetter also manufactures its customers´ vaccines, including that for the H1N1 virus.
Operational by the end of 2010, the Skokie facility will focus exclusively on pre-clinical through Phase IIb projects and will fill very small quantities of product, required for early studies. For Phase III the projects will be transferred to the company’s German facilities for large-scale production. The new facility to be located in Chicago, IL.
“Since nearly half of our customer base is located in North America, creating a U.S. facility was the logical next step,” said Peter Soelkner, Vetter`s managing director.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.